MEDA PHARMA GMBH & CO. KG
Patent Owner
Stats
- 46 US PATENTS IN FORCE
- 0 US APPLICATIONS PENDING
- Mar 12, 2015 most recent publication
Details
- 46 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 1,145 Total Citation Count
- Mar 24, 1986 Earliest Filing
- 27 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
| Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
- No Recent Publications to Display
Recent Patents
Patent #
Title
Filing Date
Issue Date
Intl Class
8518918 Combination of anticholinergics, β2-adrenoceptor agonists, antileukotrienes (leukotriene receptor antagonists), glucocorticoids and/or phosphodiesterase 4 inhibitors for the treatment of inflammatory diseasesSep 23, 11Aug 27, 13[A61K]
8268864 Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseasesMar 16, 06Sep 18, 12[A61K, A01N, C07D]
8097605 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseaseFeb 03, 09Jan 17, 12[A61K]
8048910 Combination of R,R-glycopyrrolate, rolipram, and budesonide for the treatment of inflammatory diseasesDec 21, 06Nov 01, 11[A61K]
7985766 Combination of anticholineric and β mimetics for the treatment of respiratory diseasesJul 30, 07Jul 26, 11[A61K]
7569598 Process for the preparation of the R,R (or S,S) configured glycopyrronium stereoisomerDec 18, 03Aug 04, 09[A61K, C07D]
7253182 Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicamentsJun 23, 03Aug 07, 07[A61K]
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
8557851 Combinations of flupirtine and sodium channel inhibiting substances for treating painsExpiredMar 12, 09Oct 15, 13[A61K]
2009/0142,407 Solid peptide preparations for inhalation and their preparationAbandonedJun 04, 08Jun 04, 09[A61K]
2008/0095,741 R-(+)-alpha-liponic acid for the prevention of diabetesAbandonedApr 18, 07Apr 24, 08[A61K, A61P]
2005/0288,265 Novel combination of glucocorticoids and pde-4 inhibitors for treating respiratory diseases, allegic diseases, asthma and copdAbandonedFeb 09, 05Dec 29, 05[A61K]
2005/0222,102 Treatment of rhinitis with anticholinergics alone or in combination with antihistamines, phosphodiesterase 4 inhibitors, or corticosteroidsAbandonedFeb 07, 05Oct 06, 05[A61K]
2005/0175,547 Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseasesAbandonedFeb 07, 05Aug 11, 05[A61K, A61L]
2005/0175,548 Combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPDAbandonedFeb 07, 05Aug 11, 05[A61K, A61L]
2005/0175,549 Novel combination of anticholinergic and ss mimetics for the treatment of respiratory diseasesAbandonedFeb 07, 05Aug 11, 05[A61K, A61L]
2005/0089,559 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating painsAbandonedDec 05, 03Apr 28, 05[A61K]
2005/0014,677 Solid peptide preparations for inhalation and their preparationAbandonedMar 23, 04Jan 20, 05[A61K]
6300370 Camomile oils having a high content of natural poly-ynes and process for their preparationExpiredJun 10, 98Oct 09, 01[A61K]
6013815 Production and use of salts of 6,8-bis (amidiniumthio)-octanoic acidExpiredMar 18, 98Jan 11, 00[C07B]
5998403 Salts of azelastine having improved solubility useful at providing a cytoprotective effectExpiredJul 28, 98Dec 07, 99[A61K]
Top Inventors for This Owner
| Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.
